Business Context and Reporting Period
This Form 10-Q covers Eli Lilly and Company for the quarter and six months ended June 30, 2002. The company operates primarily in pharmaceutical products, with a non-material animal health segment. The reporting period reflects significant headwinds from the loss of exclusivity for Prozac, offset by strong growth in newer products like Zyprexa and Humalog.
Key Financial Metrics
| Metric | Q2 2002 | Q2 2001 | 6M 2002 | 6M 2001 |
|---|---|---|---|---|
| Net Sales ($ millions) | 2,775.2 | 3,033.5 | 5,336.3 | 5,839.2 |
| Net Income ($ millions) | 658.5 | 827.7 | 1,287.7 | 1,634.5 |
| Earnings Per Share (Diluted) | $0.61 | $0.76 | $1.18 | $1.50 |
| Gross Margin (%) | 81.1% | 82.8% | 80.2% | 82.1% |
| Operating Cash Flow ($ millions) | N/A | N/A | 806.5 | 1,547.6 |
| Total Debt ($ millions) | 3,978.5 | N/A | 3,978.5 | 3,418.4 |
| Cash & Equivalents ($ millions) | 3,051.2 | N/A | 3,051.2 | 2,702.3 |
Note: Total debt includes short-term borrowings of $479.4 million and long-term debt of $3,499.1 million as of June 30, 2002.
Material Changes vs. Prior Period
- Revenue Decline: Net sales decreased 9% in Q2 and 9% for the six-month period compared to 2001. This was primarily driven by a 72% drop in fluoxetine (Prozac) sales due to generic competition entering the U.S. market in August 2001.
- Profitability Pressure: Net income fell 20% in Q2 and 21% for the six-month period. Gross margins declined due to the lower-margin mix resulting from the Prozac decline, despite growth in higher-margin products.
- Product Growth: Excluding Prozac, sales increased 11% in Q2. Key growth drivers included Zyprexa (+23% Q2), Humalog (+41% Q2), and Gemzar (+36% Q2).
- Expense Management: Operating expenses remained flat. R&D expenses decreased 3% due to lower incentive compensation and late-stage trial costs, while marketing expenses increased 2% due to sales force expansion.
- Debt Increase: Total debt increased by approximately $560 million from year-end 2001, primarily due to the issuance of $500 million in 10-year notes in March 2002.
Guidance, Outlook, and Risks
Management Guidance
- Q3 2002 EPS: Expected to be in the range of $0.67 to $0.69, excluding unusual items.
- Full Year 2002: Sales expected to be slightly lower than 2001. EPS expected to be $2.60 to $2.62. Gross margins expected to decline 1.0 to 1.5 percentage points.
- 2003 Outlook: Management expects earnings growth, contingent on the resolution of FDA manufacturing issues and successful new product launches.
Key Risks and Contingencies
- FDA Manufacturing Issues: The company received a warning letter regarding Good Manufacturing Practices (cGMP) at its Indianapolis facilities. Resolution is required for the approval of new products like Zyprexa IntraMuscular, Forteo, and Cymbalta. Failure to correct deficiencies could lead to production interruptions or fines.
- Patent Litigation: Ongoing lawsuits with Zenith Goldline and Dr. Reddy's Laboratories regarding generic versions of Zyprexa. An unfavorable outcome could materially impact operations.
- Legal Investigations: A grand jury subpoena was received in July 2002 regarding the marketing of Evista for unapproved uses. The company believes its policies are lawful.
- Pricing Pressures: Increasing government and state-level pressure on pharmaceutical pricing and potential patent law changes pose risks to future margins.
Investor Verification Checklist
- Verify the timeline for FDA reinspection of Indianapolis facilities and its impact on the launch of Zyprexa IntraMuscular, Forteo, and Cymbalta.
- Monitor the status of the Zyprexa patent litigation against Zenith and Dr. Reddy's, with a trial expected in Q4 2003.
- Assess the sustainability of sales growth in Zyprexa, Humalog, and Gemzar to offset the permanent loss of Prozac revenue.
- Review the outcome of the Department of Justice investigation regarding Evista marketing practices.
- Track the company's ability to maintain gross margins as the product mix shifts away from Prozac and toward newer, potentially more competitive products.